

Population 2012

14 million

| Estimates of TB burden * 2012 | Number (thousands) | Rate (per 100 000 population) |
|-------------------------------|--------------------|-------------------------------|
| Mortality (excludes HIV+TB) | 2.7 (1.2–4.8) | 20 (8.8–35) |
| Mortality (HIV+TB only) | 0.48 (0.4–0.54) | 3.5 (2.9–3.9) |
| Prevalence (includes HIV+TB) | 30 (15–50) | 219 (108–368) |
| Incidence (includes HIV+TB) | 19 (16–22) | 137 (113–163) |
| Incidence (HIV+TB only) | 1.7 (1.4–2) | 12 (9.9–14) |
| Case detection, all forms (%) | 65 (55–79) | |

TB case notifications 2012

| New cases | (%) | Retreatment cases | (%) |
|--------------------------|---------------|--------------------------|--------------|
| Smear-positive | 8 448 (72) | Relapse | 538 (49) |
| Smear-negative | 1 567 (13) | Treatment after failure | 141 (13) |
| Smear-unknown / not done | 188 (2) | Treatment after default | 181 (17) |
| Extrapulmonary | 1 524 (13) | Other | 232 (21) |
| Other | 0 (0) | | |
| Total new | 11 727 | Total retreatment | 1 092 |

| | | | |
|------------------------------|---------------|-----------------------------|---------------|
| Other (history unknown) | 0 | | |
| Total new and relapse | 12 265 | Total cases notified | 12 819 |

| New cases | Smear-positive | Smear-negative/ unknown/ not done | Extrapulmonary |
|-----------|----------------|-----------------------------------|----------------|
| M:F ratio | 2.3 | | |
| Age < 15 | 209 | 262 | 221 |

| Laboratories | 2012 |
|--|-----------------|
| Smear (per 100 000 population) | 0.8 |
| Culture (per 5 million population) | 1.1 |
| Drug susceptibility testing (per 5 million population) | 0.7 |
| Is second-line drug susceptibility testing available? | Yes, in country |

| Treatment success rate 2011 (%) | | |
|--|----|---|
| New smear-positive and/or culture-positive | 85 | Is rifampicin used throughout treatment for new patients? |
| New smear-negative/extrapulmonary | 76 | |
| Retreatment | 68 | Yes |


| TB/HIV 2012 | Number | (%) |
|---|--------|------|
| TB patients with known HIV status | 10 048 | (78) |
| HIV-positive TB patients | 882 | (9) |
| HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) | 793 | (90) |
| HIV-positive TB patients on antiretroviral therapy (ART) | 561 | (64) |
| HIV-positive people screened for TB | | |
| HIV-positive people provided with IPT | 426 | |

| Estimates of MDR-TB burden 2012* | New | Retreatment |
|--|----------------|--------------|
| % of TB cases with MDR-TB | 2.1 (0.69–4.9) | 17 (7–31) |
| MDR-TB cases among notified pulmonary TB cases | 220 (70–500) | 180 (76–340) |

| Reported cases of MDR-TB 2012 | New | Retreatment | Total |
|--------------------------------------|----------|-------------|-------|
| Cases tested for MDR-TB | 25 (<1%) | 113 (10%) | 147 |
| Laboratory-confirmed MDR-TB cases | 1 | 24 | 27 |
| Patients started on MDR-TB treatment | | | 32 |


| Financing TB control | 2013 |
|--|------|
| National TB programme budget (US\$ millions) | 6 |
| % Funded domestically | 33% |
| % Funded internationally | 67% |
| % Unfunded | 0% |

(Rate per 100 000 population per year)




Mortality (excludes HIV+TB)

(Rate per 100 000 population)




Prevalence

(Rate per 100 000 population per year)




Notifications Incidence Incidence (HIV+TB only)

Treatment success rate (%)




New smear-positive and/or culture-positive New smear-negative/extrapulmonary Retreatment

(Number of patients)



HIV-positive TB patients on CPT on ART

Total budget (US\$ millions)



Funded domestically Funded internationally Unfunded